Whalesbook
Yaar, Alembic Pharma ka US market mein kaafi bada plan chal raha hai. Bol rahe hain ki FY27 tak US business ko 10-15% tak badhayenge. Iske liye 15 se zyada naye products launch karne ka goal hai, jismein kuch niche markets aur complex generics bhi hain. Waise, US se toh unki 30% revenue aati hai, jo FY26 mein ₹2,206 Crore thi. Analysts bhi keh rahe hain ki aane wale 2 saal mein US market mein mid-teen growth dekhne ko milegi, kyunki launch calendar kaafi strong hai. Aim hai US market mein price increase aur zyada sales volume ka fayda uthana. Currently, company ka market value ₹14,138 Crore se ₹15,441 Crore ke beech hai.
Margin Rebound Ka Mushkil Safar
Par bhai, sab kuch itna easy nahi hai. Profitability par current mein pressure hai. Unka EBITDA margin Q4 FY26 mein gir kar sirf 12.3% ho gaya tha. Iska reason hai US branded business mein badha investment, pipeline development, naye plants aur zyada R&D spending. Management ko umeed hai ki 2 se 3 saal mein margins wapas 20% tak aa jayenge, jab capacity use badhegi aur complex products se revenue aayegi. Lekin, analysts warn kar rahe hain ki US branded segment ki wajah se FY27 mein margins 100-150 basis points tak kam ho sakte hain. Agar historical data dekho toh PAT margin 20.67% (FY21) se 8.72% (FY25) ho gaya tha, aur operating profit margin 27.45% se 15.11% ho gaya.
Industry Trend Aur Competition
Alembic complex generics aur specialty therapies ki taraf jaa raha hai, kyunki standard generics mein competition badh raha hai aur margins kam ho rahe hain. Ye trend poore industry mein hai. Global complex generics market 2032-2035 tak $180-200 billion tak pahunch sakta hai. Baaki companies se compare karein toh Alembic ka P/E ratio ( 19.4-32.6 ) Sun Pharma ( 34.7-41.0 ) aur Cipla ( 28.4-29.9 ) se kam hai, jabki Dr. Reddy's ( 17.3-26.9 ) se zyada hai. Sun Pharma ka market cap ₹4.5 lakh Crore aur Cipla ka ₹1.1 lakh Crore hai, jo Alembic se kaafi bade hain. Nifty Pharma index ka P/E 38.7 hai. Alembic ka complex generics pe focus achha ho sakta hai, par large investments aur approval timelines mein risks hain. Unka domestic business bhi slow hai, sirf 4-5% growth dikha raha hai.
Target Par Skepticism
Bahut log 20% EBITDA margin target par doubt kar rahe hain, kyunki current performance aur tough market conditions hain. Company ki historical margin contraction dikha rahi hai ki profitability mein issues hain. US market mein intense pricing pressure hai aur US FDA ki scrutiny bhi zyada hai. US branded segment aur complex generics mein large investments karna long-term ke liye sahi ho sakta hai, par short-term mein profits kam hi rahenge. Dr. Reddy's Laboratories jaisi companies ne better P/E aur consistent growth maintain kiya hai, jabki Alembic ki sales paanch saal mein sirf 6.37% badhi hai. Strategy 'sweating existing assets' par depend karti hai, jiske liye perfect execution chahiye. Current analyst targets ₹940-₹991 hain, jo 20-26% upside dikhate hain, par ye un execution risks ko poora consider nahi karta.
Future Outlook Aur Challenges
Alembic Pharma management apne growth strategy par confident hai, especially US expansion aur high-value products par. Woh Rest of World business se 15% growth aur API segment mein modest expansion forecast kar rahe hain. Analysts expect kar rahe hain ki 2027 tak revenue 11% annually badhegi. Shareholder value isi baat par depend karegi ki Alembic US market challenges ko kaise handle karta hai, investments manage karta hai, aur apne product pipeline ko better margins mein badal pata hai ya nahi.